Business
Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021
AUSTIN, Texas, Dec. 9, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest
About this update from Natera, Inc.
[{"type":"text","content":"AUSTIN, Texas, Dec. 9, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest findings presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, from December 7-10, 2021. Natera is presenting two studies based on the use of Signatera in high-risk breast cancer patients.\n\n \n \n \n \n \n \n\n \nDetection of circulating tumor DNA post neoadjuvant chemotherapy using personalized assay is associated with disease relapsePoster Presentation: P2-01-06 | Presenter: Elisa Agostinetto, M.D.\nIn this study, Signatera was used for the detection and monitoring of ctDNA in 44 patients with early breast cancer across all major subtypes, before and after standard neoadjuvant chemotherapy, and then post-surgery with a median clinical follow up of 3 years. The study demonstrated that ctDNA status before surgery and at the last follow up were the strongest predictors of patient outcomes after adjusting for all clinico-pathological risk factors such as stage, histology, tumor size and Ki67 status.\nDetection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgeryPoster presentation: P2-01-10 | Presenter: Isaac Garcia-Murillas, Ph.D.\nThis study assessed ctDNA status before surgery, after surgery prior to the start of adjuvant chemotherapy and after adjuvant chemotherapy, in 48 patients with early breast cancer across all major subtypes. ctDNA was detected in 29% of patients after surgery (prior to adjuvant treatment), including 20% in the ER-positive subgroup. Furthermore, results indicated that among patients who were ctDNA-positive after surgery, the majority benefited from adjuvant chemotherapy and did not relapse. Among patients who remained ctDNA-positive after adjuvant treatment, 100% relapsed.\n\"These studies show that Signatera can help fill in insight gaps that traditional tools, such as scans and blood tests, can't capture in early breast cancer patients,\" said Angel Rodriguez, M.D., medical director of oncology at Natera. \"Not only did we see the efficacy of adjuvant therapy, but the importance of Signatera as a tool to help dramatically improve our understanding of each patient's risk for recurrence, enabling us to more thoroughly monitor their disease and potentially ch...